Global Osteoporosis Drugs Market Analysis and Forecast 2024-2030

Global Osteoporosis Drugs Market Analysis and Forecast 2024-2030


Summary

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.

According to APO Research, The global Osteoporosis Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Osteoporosis Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Osteoporosis Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Osteoporosis Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Osteoporosis Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Osteoporosis Drugs include Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Osteoporosis Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Osteoporosis Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Osteoporosis Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Osteoporosis Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Osteoporosis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Osteoporosis Drugs sales, projected growth trends, production technology, application and end-user industry.

Osteoporosis Drugs segment by Company

Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Osteoporosis Drugs segment by Type

Antiresorptive Drugs
Anabolic Drugs
Osteoporosis Drugs segment by Application

Female
Male
Osteoporosis Drugs segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoporosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Osteoporosis Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Osteoporosis Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Osteoporosis Drugs Market by Type
1.2.1 Global Osteoporosis Drugs Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Antiresorptive Drugs
1.2.3 Anabolic Drugs
1.3 Osteoporosis Drugs Market by Application
1.3.1 Global Osteoporosis Drugs Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Female
1.3.3 Male
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Osteoporosis Drugs Market Dynamics
2.1 Osteoporosis Drugs Industry Trends
2.2 Osteoporosis Drugs Industry Drivers
2.3 Osteoporosis Drugs Industry Opportunities and Challenges
2.4 Osteoporosis Drugs Industry Restraints
3 Global Market Growth Prospects
3.1 Global Osteoporosis Drugs Revenue Estimates and Forecasts (2019-2030)
3.2 Global Osteoporosis Drugs Revenue by Region
3.2.1 Global Osteoporosis Drugs Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Osteoporosis Drugs Revenue by Region (2019-2024)
3.2.3 Global Osteoporosis Drugs Revenue by Region (2025-2030)
3.2.4 Global Osteoporosis Drugs Revenue Market Share by Region (2019-2030)
3.3 Global Osteoporosis Drugs Sales Estimates and Forecasts 2019-2030
3.4 Global Osteoporosis Drugs Sales by Region
3.4.1 Global Osteoporosis Drugs Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Osteoporosis Drugs Sales by Region (2019-2024)
3.4.3 Global Osteoporosis Drugs Sales by Region (2025-2030)
3.4.4 Global Osteoporosis Drugs Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 Market Competitive Landscape by Manufacturers
4.1 Global Osteoporosis Drugs Revenue by Manufacturers
4.1.1 Global Osteoporosis Drugs Revenue by Manufacturers (2019-2024)
4.1.2 Global Osteoporosis Drugs Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Osteoporosis Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Osteoporosis Drugs Sales by Manufacturers
4.2.1 Global Osteoporosis Drugs Sales by Manufacturers (2019-2024)
4.2.2 Global Osteoporosis Drugs Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Osteoporosis Drugs Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Osteoporosis Drugs Sales Price by Manufacturers (2019-2024)
4.4 Global Osteoporosis Drugs Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Osteoporosis Drugs Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Osteoporosis Drugs Manufacturers, Product Type & Application
4.7 Global Osteoporosis Drugs Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Osteoporosis Drugs Market CR5 and HHI
4.8.2 2023 Osteoporosis Drugs Tier 1, Tier 2, and Tier 3
5 Osteoporosis Drugs Market by Type
5.1 Global Osteoporosis Drugs Revenue by Type
5.1.1 Global Osteoporosis Drugs Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Osteoporosis Drugs Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Osteoporosis Drugs Revenue Market Share by Type (2019-2030)
5.2 Global Osteoporosis Drugs Sales by Type
5.2.1 Global Osteoporosis Drugs Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Osteoporosis Drugs Sales by Type (2019-2030) & (K Units)
5.2.3 Global Osteoporosis Drugs Sales Market Share by Type (2019-2030)
5.3 Global Osteoporosis Drugs Price by Type
6 Osteoporosis Drugs Market by Application
6.1 Global Osteoporosis Drugs Revenue by Application
6.1.1 Global Osteoporosis Drugs Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Osteoporosis Drugs Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Osteoporosis Drugs Revenue Market Share by Application (2019-2030)
6.2 Global Osteoporosis Drugs Sales by Application
6.2.1 Global Osteoporosis Drugs Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Osteoporosis Drugs Sales by Application (2019-2030) & (K Units)
6.2.3 Global Osteoporosis Drugs Sales Market Share by Application (2019-2030)
6.3 Global Osteoporosis Drugs Price by Application
7 Company Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Comapny Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Eli Lilly Osteoporosis Drugs Product Portfolio
7.1.5 Eli Lilly Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Novartis Osteoporosis Drugs Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Pfizer
7.3.1 Pfizer Comapny Information
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 Pfizer Osteoporosis Drugs Product Portfolio
7.3.5 Pfizer Recent Developments
7.4 Amgen
7.4.1 Amgen Comapny Information
7.4.2 Amgen Business Overview
7.4.3 Amgen Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 Amgen Osteoporosis Drugs Product Portfolio
7.4.5 Amgen Recent Developments
7.5 Merck
7.5.1 Merck Comapny Information
7.5.2 Merck Business Overview
7.5.3 Merck Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Merck Osteoporosis Drugs Product Portfolio
7.5.5 Merck Recent Developments
7.6 Novo nordisk
7.6.1 Novo nordisk Comapny Information
7.6.2 Novo nordisk Business Overview
7.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Novo nordisk Osteoporosis Drugs Product Portfolio
7.6.5 Novo nordisk Recent Developments
7.7 Actavis
7.7.1 Actavis Comapny Information
7.7.2 Actavis Business Overview
7.7.3 Actavis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Actavis Osteoporosis Drugs Product Portfolio
7.7.5 Actavis Recent Developments
7.8 Roche
7.8.1 Roche Comapny Information
7.8.2 Roche Business Overview
7.8.3 Roche Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 Roche Osteoporosis Drugs Product Portfolio
7.8.5 Roche Recent Developments
8 North America
8.1 North America Osteoporosis Drugs Market Size by Type
8.1.1 North America Osteoporosis Drugs Revenue by Type (2019-2030)
8.1.2 North America Osteoporosis Drugs Sales by Type (2019-2030)
8.1.3 North America Osteoporosis Drugs Price by Type (2019-2030)
8.2 North America Osteoporosis Drugs Market Size by Application
8.2.1 North America Osteoporosis Drugs Revenue by Application (2019-2030)
8.2.2 North America Osteoporosis Drugs Sales by Application (2019-2030)
8.2.3 North America Osteoporosis Drugs Price by Application (2019-2030)
8.3 North America Osteoporosis Drugs Market Size by Country
8.3.1 North America Osteoporosis Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Osteoporosis Drugs Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Osteoporosis Drugs Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 Europe
9.1 Europe Osteoporosis Drugs Market Size by Type
9.1.1 Europe Osteoporosis Drugs Revenue by Type (2019-2030)
9.1.2 Europe Osteoporosis Drugs Sales by Type (2019-2030)
9.1.3 Europe Osteoporosis Drugs Price by Type (2019-2030)
9.2 Europe Osteoporosis Drugs Market Size by Application
9.2.1 Europe Osteoporosis Drugs Revenue by Application (2019-2030)
9.2.2 Europe Osteoporosis Drugs Sales by Application (2019-2030)
9.2.3 Europe Osteoporosis Drugs Price by Application (2019-2030)
9.3 Europe Osteoporosis Drugs Market Size by Country
9.3.1 Europe Osteoporosis Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Osteoporosis Drugs Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Osteoporosis Drugs Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 China
10.1 China Osteoporosis Drugs Market Size by Type
10.1.1 China Osteoporosis Drugs Revenue by Type (2019-2030)
10.1.2 China Osteoporosis Drugs Sales by Type (2019-2030)
10.1.3 China Osteoporosis Drugs Price by Type (2019-2030)
10.2 China Osteoporosis Drugs Market Size by Application
10.2.1 China Osteoporosis Drugs Revenue by Application (2019-2030)
10.2.2 China Osteoporosis Drugs Sales by Application (2019-2030)
10.2.3 China Osteoporosis Drugs Price by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Osteoporosis Drugs Market Size by Type
11.1.1 Asia Osteoporosis Drugs Revenue by Type (2019-2030)
11.1.2 Asia Osteoporosis Drugs Sales by Type (2019-2030)
11.1.3 Asia Osteoporosis Drugs Price by Type (2019-2030)
11.2 Asia Osteoporosis Drugs Market Size by Application
11.2.1 Asia Osteoporosis Drugs Revenue by Application (2019-2030)
11.2.2 Asia Osteoporosis Drugs Sales by Application (2019-2030)
11.2.3 Asia Osteoporosis Drugs Price by Application (2019-2030)
11.3 Asia Osteoporosis Drugs Market Size by Country
11.3.1 Asia Osteoporosis Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Osteoporosis Drugs Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Osteoporosis Drugs Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 Middle East, Africa and Latin America
12.1 MEALA Osteoporosis Drugs Market Size by Type
12.1.1 MEALA Osteoporosis Drugs Revenue by Type (2019-2030)
12.1.2 MEALA Osteoporosis Drugs Sales by Type (2019-2030)
12.1.3 MEALA Osteoporosis Drugs Price by Type (2019-2030)
12.2 MEALA Osteoporosis Drugs Market Size by Application
12.2.1 MEALA Osteoporosis Drugs Revenue by Application (2019-2030)
12.2.2 MEALA Osteoporosis Drugs Sales by Application (2019-2030)
12.2.3 MEALA Osteoporosis Drugs Price by Application (2019-2030)
12.3 MEALA Osteoporosis Drugs Market Size by Country
12.3.1 MEALA Osteoporosis Drugs Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Osteoporosis Drugs Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Osteoporosis Drugs Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 Value Chain and Sales Channels Analysis
13.1 Osteoporosis Drugs Value Chain Analysis
13.1.1 Osteoporosis Drugs Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Osteoporosis Drugs Production Mode & Process
13.2 Osteoporosis Drugs Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Osteoporosis Drugs Distributors
13.2.3 Osteoporosis Drugs Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings